u/Many-Guess5625

Not new information, but it’s good to see Novo laying it out so clearly in Earnings Call Slides:

We can see a rapid growth in NBRx for Wegovy once Wegovy pill was introduced, outpacing LLY‘s tirzepatide almost 2:1. It’s only a matter of time until this trend shows up in the market share numbers.

Additionally, the graph on the pill slide shows no sign of slowing or even negative sales growth ( as reported by symphony last week)

Source: https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/financial-results/2026/Q1-2026-investor-presentation.pdf